Glycobia Inc Profile last edited on: 11/21/19
CAGE: 50VV0
UEI: JNVRYXCFG2G3
Business Identifier: Immunotherapy 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 23
County: Tompkins
Congr. District: 23
County: Tompkins
Public Profile
With very close ties to Cornell on many levels, Glycobia is leveraging a proven technology platform for bottom-up assembly of diverse cancer-related glycan antigens that enables discovery of novel cancer immunotherapeutics. This technology is described as generating glycan-specific antibodies by stimulating an immune response to novel glycoconjugates comprising bioengineered human glycan structures. This breakthrough allows privileged access to therapeutically validated glycan targets that are not naturally recognized by the immune system. Using this approach, Glycobia is actively developing immunotherapies against structural signatures of cancer.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2019 | 1 | NIH | $300,000 | |
| Project Title: Novel Strategy To Generate Glycan-Specific Antibodies For Cancer Immunotherapy | ||||
| 2017 | 1 | NIH | $150,000 | |
| Project Title: N-glycan specific antibodies for advancing glycobiology research | ||||
| 2016 | 2 | NIH | $1,601,138 | |
| Project Title: Glycoconjugate Therapeutic Peptides for Improved Treatment of Human Diseases | ||||
| 2015 | 2 | NIH | $1,396,543 | |
| Project Title: Conjugation of Polysialic Acid to Biologics in Glycoengineered Escherichia Coli | ||||
| 2013 | 1 | NIH | $299,450 | |
| Project Title: BOTTOM-UP GLYCOENGINEERING LIBRARY of N-GLYCANS | ||||
Key People / Management
Matthew DeLisa
Adam C Fisher
Brian Green -- Senior Director of R&D
Brian Hamilton
Judith H Merritt -- Chief Science Officer
Adam C Fisher
Brian Green -- Senior Director of R&D
Brian Hamilton
Judith H Merritt -- Chief Science Officer
